Mithra Announces Very Promising Hemostasis Results for Estelle®

  • Results point to minimal changes in markers of coagulation and fibrinolysis, which is key to further delineate unique safety potential of Estelle®
  • Detailed results available in coming weeks, with presentations at scientific conferences planned in Q1/Q2

Liège, Belgium, 08 February 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that the company obtained promising results for its Phase II hemostasis study of Estelle®, Mithra’s combined oral contraceptive (COC) candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).